Brokerages Set AstraZeneca PLC (LON:AZN) Price Target at GBX 7,542.80

Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is GBX 7,542.80 ($97.40).

A number of equities analysts recently commented on AZN shares. JPMorgan Chase & Co. reissued an "overweight" rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research note on Friday, March 7th. Finally, Berenberg Bank reaffirmed a "buy" rating and set a GBX 140 ($1.81) price objective on shares of AstraZeneca in a research report on Monday, January 27th.

AstraZeneca Stock Down 1.3 %

Shares of LON:AZN traded down GBX 156 ($2.01) during trading hours on Friday, hitting £114.52 ($147.88). The company's stock had a trading volume of 1,003,695 shares, compared to its average volume of 24,690,625. The firm's fifty day moving average price is £115.32 and its 200 day moving average price is £113.21. AstraZeneca has a 52 week low of GBX 9,670 ($124.87) and a 52 week high of £133.88 ($172.88). The company has a market capitalization of £220.34 billion, a price-to-earnings ratio of 31.39, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.